Now showing items 1-10 of 90
Biosimilar competition: lessons from Europe
(Nature Reviews Drug Discovery, 2014-01-21)
The Pharmaceutical Industry
FISHER and TEMIN (1973) have argued recently that many empirical studies1 relating to the Schumpeterian hypothesis are inappropriate for testing that hypothesis. They observe that Schumpeter can be interpreted as hypothesizing ...
Recent Trends in Brand-Name and Generic Drug Competition
(Journal of Medical Economics, 2013)
Updated trends in US brand-name and generic drug competition
(Journal of Medical Economics, 2016-09)
Does generic entry always increase consumer welfare?
(Food Drug Law J, 2012)
This article examines how the nature of competition between brands in a therapeutic category changes after generic entry and provide a framework for analyzing the effect of generic entry on consumer welfare that takes into ...
How Did the 2003 Prescription Drug Re-Importation Bill Pass the House?
the major interest groups in the debate over allowing the re-importation of prescription drugs by utilizing a logit model and instrumental variables. Consistent with political support approach, the evidence suggests that ...
An Economic Analysis of Global Policy Proposals to Prohibit Compensation of Blood Plasma Donors
(International Journal of the Economics of Business, 2016-05-03)
© 2016 International Journal of the Economics of Business.Human blood plasma and its derivative therapies have been used therapeutically for more than 50 years, after first being widely used to treat injuries during World ...
PIONEERS, IMITATORS, AND GENERICS - A SIMULATION-MODEL OF SCHUMPETERIAN COMPETITION
(QUARTERLY JOURNAL OF ECONOMICS, 1987-08)
Innovation in the pharmaceutical industry: New estimates of R&D costs.
(J Health Econ, 2016-05)
The research and development costs of 106 randomly selected new drugs were obtained from a survey of 10 pharmaceutical firms. These data were used to estimate the average pre-tax cost of new drug and biologics development. ...